Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Non-Current Assets (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Other Non-Current Assets for 11 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 4.8% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, down 4.8% year-over-year, with the annual reading at $2.7 million for FY2025, 4.8% down from the prior year.
  • Other Non-Current Assets hit $2.7 million in Q4 2025 for Voyager Therapeutics, down from $5.6 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.6 million in Q3 2025 to a low of $1.5 million in Q2 2022.
  • Historically, Other Non-Current Assets has averaged $2.3 million across 5 years, with a median of $2.0 million in 2021.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 32.58% in 2022 and later skyrocketed 95.34% in 2025.
  • Year by year, Other Non-Current Assets stood at $1.8 million in 2021, then fell by 14.84% to $1.5 million in 2022, then increased by 5.15% to $1.6 million in 2023, then skyrocketed by 80.41% to $2.9 million in 2024, then dropped by 4.8% to $2.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for VYGR at $2.7 million in Q4 2025, $5.6 million in Q3 2025, and $2.9 million in Q2 2025.